Investigated
Are there clinical examples of ecDNA-targeted therapies?
Short answer
Image: cancer.gov
Clinical development has begun, but demonstrated patient benefit has not. BBI-940 is described as entering a first-in-human phase 1 study, while the best-documented ecDNA-selective approaches—including CHK1 inhibition—remain preclinical.
The views on this question
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Clinical Frontier
Source weight 40%Lens adapted to this topic: Early trials and emerging strategies
A narrower reading highlights that the field has crossed from laboratory research into clinical testing: BBI-940 is described as the first direct ecDNA-targeting asset entering phase 1. That is a genuine clinical example of an investigational therapy, but it should not be conflated with proof that ecDNA targeting works in patients.
- BBI-940 is described as a direct ecDNA-targeting kinesin degrader and the company’s first clinical-stage asset.
- The reported mechanism aims to eliminate ecDNA by preventing its segregation onto chromosomes during mitosis.
- The same account identifies unproven clinical efficacy and possible toxicity as important risks.
- Other direct approaches, including CRISPR-based ecDNA degradation, remain proof-of-concept work in cancer cell lines rather than clinical therapies.
Follow the white rabbit
Deeper threads worth pulling on next.
- How does ecDNA drive cancer evolution?Different angle, same storyUnderstanding how extrachromosomal DNA fuels tumor heterogeneity and drug resistance explains its appeal as a therapeutic target.
- CHK1 inhibitors and ecDNA-selectivityDifferent angle, same storySurveying preclinical CHK1 data highlights the best evidence for ecDNA-selective vulnerability and translational hurdles.
- BBI-940 first-in-human trial details